February 21, 2026 — RNews

#steatohepatitis — Saturday, February 21, 2026 (1 items)

hot top new

← prev day next day →

0

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)

Noureddin M … Loomba R The Lancet 2026-02-21

#clinical trial #therapeutics #fibrosis #steatohepatitis